Enliven Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 6.83M | $267.71M | 0.01% | Trimmed-3.9% | 2026-03-31 |
| StateStreet | passive | 1.09M | $42.77M | 0.00% | Added+3.6% | 2026-03-31 |
| DEShaw | quant | 193.5K | $7.59M | 0.00% | New | 2026-03-31 |
| Wellington | fundamental | 150.1K | $5.88M | 0.00% | Added+15.6% | 2026-03-31 |
| TRowePrice | fundamental | 97.7K | $3.83K | 0.00% | Added+310.7% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-12upcoming | -0.40 | — | — |
| 2026-05-07 | -0.41 | -0.38 | +7.32% |
| 2026-03-03 | -0.47 | -0.48 | -1.05% |
| 2025-11-12 | -0.46 | -0.32 | +31.18% |
| 2025-08-13 | -0.42 | -0.49 | -16.67% |
| 2025-05-14 | -0.50 | -0.57 | -13.03% |
| 2025-03-13 | -0.52 | -0.46 | +11.11% |
| 2024-11-13 | -0.50 | -0.48 | +4.36% |
| 2024-08-13 | -0.56 | -0.41 | +27.05% |
| 2024-05-14 | -0.57 | -0.54 | +4.71% |
| 2024-03-14 | -0.54 | -0.47 | +12.96% |
| 2023-11-09 | -0.47 | -0.51 | -7.94% |
| 2023-08-10 | -0.40 | -0.41 | -3.36% |
| 2023-05-11 | -0.52 | -0.80 | -53.85% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ELVN | -5.11% | +37.63% | +156.95% | +122.68% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -8.08% | +42.27% | +160.39% | +109.99% |